Advanced in Palmoplantar Keratoderma

Juliette Hautier-Mazereeuw

Toulouse, FR 
Advanced in Palmoplantar Keratoderma
Toulouse, FR 
OverviewLocationsClinical Research

Overview

Juliette Hautier-Mazereeuw practices in Toulouse, France. Ms. Hautier-Mazereeuw is rated as an Advanced expert by MediFind in the treatment of Palmoplantar Keratoderma. Her top areas of expertise are Netherton Syndrome, Nonbullous Congenital Ichthyosiform Erythroderma, Giant Congenital Nevus, and Lamellar Ichthyosis.

Her clinical research consists of co-authoring 168 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 6 articles in the study of Palmoplantar Keratoderma.

Gender
Female

Locations

Toulouse, France
Other Locations
Quimper, CH
Quimper, France
Dijon, France
Bordeaux, France
CHU Nantes
Nantes, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Evaluation of the Feasibility and Effect of Therapeutic Education Sessions Using an Internet Application in Hereditary Ichthyosis
Evaluation of the Feasibility and Effect of Therapeutic Education Sessions Using an Internet Application in Hereditary Ichthyosis
Enrollment Status: Completed
Publish Date: April 12, 2024
Intervention Type: Other
Study Phase: Not Applicable
Evaluation of the Efficacy of Injections of Botulinic Toxin in Plantar Lesions of Patients Suffering From Localized Epidermolysis Bullosa Simplex : Double Blind Randomized Controlled Study.
Evaluation of the Efficacy of Injections of Botulinic Toxin in Plantar Lesions of Patients Suffering From Localized Epidermolysis Bullosa Simplex : Double Blind Randomized Controlled Study.
Enrollment Status: Unknown
Publish Date: August 23, 2023
Intervention Type: Drug
Study Drug: Botulinic Toxin
Study Phase: Phase 2/Phase 3
Double-blind, Randomised, Vehicle-controlled, Phase III, Efficacy and Safety Study With 24-month Open-label Follow-up of Oleogel-S10 in Patients With Inherited Epidermolysis Bullosa
Double-blind, Randomised, Vehicle-controlled, Phase III, Efficacy and Safety Study With 24-month Open-label Follow-up of Oleogel-S10 in Patients With Inherited Epidermolysis Bullosa
Enrollment Status: Completed
Publish Date: July 20, 2023
Intervention Type: Drug
Study Drug: Oleogel-S10
Study Phase: Phase 3
Evaluation of Effect and Tolerance of the Association of Baricitinib (4 mg) and Phototherapy Versus Phototherapy in Adults With Progressive Vitiligo: a Randomized, Double-blind, Prospective, Non-comparative Phase II Study.
Evaluation of Effect and Tolerance of the Association of Baricitinib (4 mg) and Phototherapy Versus Phototherapy in Adults With Progressive Vitiligo: a Randomized, Double-blind, Prospective, Non-comparative Phase II Study.
Enrollment Status: Completed
Publish Date: June 13, 2023
Intervention Type: Drug
Study Drug: Baricitinib Oral Product
Study Phase: Phase 2
A Phase 3, Multi-center, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of SD-101 Cream in Patients With Epidermolysis Bullosa
A Phase 3, Multi-center, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of SD-101 Cream in Patients With Epidermolysis Bullosa
Enrollment Status: Completed
Publish Date: April 09, 2020
Intervention Type: Drug
Study Phase: Phase 3
Treatment of Superficial Voluminous Complicated Slow-flow Vascular Malformations With Sirolimus: a Phase 2 Trial in Children Observational-phase Designed
Treatment of Superficial Voluminous Complicated Slow-flow Vascular Malformations With Sirolimus: a Phase 2 Trial in Children Observational-phase Designed
Enrollment Status: Completed
Publish Date: September 18, 2019
Intervention Type: Drug
Study Phase: Phase 2
Rationalization of the Treatment Pathway of Patient Suffering From Rare Skin Disease With Telemedicine
Rationalization of the Treatment Pathway of Patient Suffering From Rare Skin Disease With Telemedicine
Enrollment Status: Completed
Publish Date: November 20, 2018
Intervention Type: Procedure
Study Phase: Not Applicable
Non-randomised Open Label Pilot Study of Sirolimus Therapy for Segmental Overgrowth Due to PIK3CA- Related Overgrowth
Non-randomised Open Label Pilot Study of Sirolimus Therapy for Segmental Overgrowth Due to PIK3CA- Related Overgrowth
Enrollment Status: Completed
Publish Date: October 02, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 7 Less Clinical Trials

168 Total Publications

New Gene-based Classification of Ichthyoses and Palmoplantar Keratodermas: Hereditary Epidermal Differentiation Disorders.
New Gene-based Classification of Ichthyoses and Palmoplantar Keratodermas: Hereditary Epidermal Differentiation Disorders.
Journal: Journal of the American Academy of Dermatology
Published: July 22, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Hautier-Mazereeuw's expertise for a condition
ConditionClose
View All 29 Advanced Conditions
View All 77 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile